CD200/CD200R1 activation alleviates central sensitization in chronic migraine via STAT6.

Chronic migraine (CM) involves a process called central sensitization (CS). This process is influenced by microglial activation in the brain. Researchers studied the CD200/CD200R1 pathway, which helps regulate immune responses. They created a mouse model of CM using nitroglycerin (NTG) injections. After treatment, they measured pain sensitivity and analyzed protein levels in specific brain regions. They found that NTG increased pain sensitivity and lowered CD200 and CD200R1 levels. However, using a CD200R1 agonist called CD200Fc helped reduce pain sensitivity. It did this by decreasing certain proteins linked to inflammation. CD200Fc also activated a protein called STAT6, which promotes anti-inflammatory responses. Blocking STAT6 stopped the beneficial effects of CD200Fc. This research suggests that targeting the CD200/CD200R1 pathway could be a new way to treat chronic migraine. Clinical relevance: This study indicates that targeting the CD200/CD200R1 pathway may offer new treatment options for chronic migraine patients.